Tiziana life sciences announces significant reduction in microglia activation in pet scan of moderate alzheimer's patient treated with intranasal foralumab

New york, may 09, 2025 (globe newswire) -- tiziana life sciences, ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-cd3 monoclonal antibody, today announced results of a pet scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate alzheimer's disease (ad) who was treated for three months with intranasal foralumab under an expanded access program. the microglial tspo pet scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with alzheimer's disease progression.
PET Ratings Summary
PET Quant Ranking